PRINCETON, N.J., Aug. 2, 2011 /PRNewswire/ -- Informex, the leading meeting place for buyers and sellers of high-value chemistry, today announced the introduction of a new conference, 'Business Strategies for Biologics: Positioning and Partnering for the Biopharmaceutical Evolution' to be hosted October 5-6th, 2011 in Boston, Massachusetts. The two day conference will cover on-trend topics regarding the future of pharma, sourcing strategies for biologics, regulatory challenges, and opportunities in biosimilars. Speakers will include senior personnel from Merck, Novartis, Pfizer, Sanofi, Genentech/Roche, and Boehringer Ingelheim.
"We created this new Biologics Conference to provide attendees with valuable and relevant content to help them successfully navigate the changes and challenges in the rapidly growing biologics sector," Jennifer Jessup, Global Brand Director, Informex noted. She continued, "With Industry forecasts indicating that by 2014, 50% of the top 100 and seven of the top 10 drugs will be biologics(1). This is a rare opportunity for companies to strategize and get settled into an early stage market with expectations for tremendous growth."
As the blockbuster drug patents begin to expire, a massive shift towards R&D of biologics and biosimilars has been happening industry-wide. Chemicals companies are seeing this translated into redefined global business demands. It is imperative for pharma companies to have the tools available to strategize for shifting their pipelines into this sort of R&D. The Biologics Conference will provide these tools, and will also offer valuable insight into evaluating and maximizing competitive advantages as more and more services are being outsourced globally to satisfy the market.
The Biologics conference will provide opportunities to learn from and network with department heads, directors and C-level executives from big Pharma, CMOs, CROs, CRAMs, Generics, Biotechs, and Research and Academic Institutions in one central location. Some of the featured speakers at the conference include: Merck Director of Scientific Liaison Biologics, Stephen O'Keefe, Sanofi US VP of Regulatory Policy, Brian Harvey, Boehringer Ingelheim Global Sourcing Manager, Dr. Enric Bosch Rado, and Genetech/Roche Senior Medical Director, Frank Scappaticci. The Business Strategies for Biologics complete program has been created to offer delegates a unique forum to work towards evaluating and dissecting how to take advantage of the rapidly advancing Biologics sector.
Early-bird registration will close on August 19, 2011. For more information about the Business Strategies for Biologics Conference in Boston, please visit us online at: http://www.informex.com/biologics-conference.
For more information on Informex, please visit: www.informex.com.
About UBM Live: UBM Live is a division of UBM Plc (LSE: UBM) a leading provider of business information services to the maritime, travel, fashion, technology, healthcare, media, and property industries. UBM offers services in trade shows, online, news distribution, and publishing to customers across the globe. Its brands are represented in more than 30 countries and are organized into specialist teams that serve their business communities helping them excel in their market by working effectively and efficiently. For more information, go to www.ubmlive.com.
About Informex: Organized by UBM Live, Informex is the leading meeting place for buyers and sellers of high-value chemistry for a broad range of applications. As the premier, must-attend, event for the chemical industry for the past 27 years, Informex is a marketplace for networking and doing business in the fine, custom and specialty chemical manufacturing industry. The show traces its origin to a group of members from the Society of Chemical Manufacturers and Associates (SOCMA) who were looking for an annual place to meet and do business. Each year the event brings together an international mix of more than 4,000 fine and specialty chemicals professionals and 500 exhibitors for the all encompassing, 4 day event.